Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies.

Sonnichsen D, Dorer DJ, Cortes J, Talpaz M, Deininger MW, Shah NP, Kantarjian HM, Bixby D, Mauro MJ, Flinn IW, Litwin J, Turner CD, Haluska FG.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1599-607. doi: 10.1007/s00280-013-2160-7. Epub 2013 Apr 23.

2.

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.

Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H; PACE Investigators..

N Engl J Med. 2013 Nov 7;369(19):1783-96. doi: 10.1056/NEJMoa1306494. Epub 2013 Nov 1.

3.

Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Shamroe CL, Comeau JM.

Ann Pharmacother. 2013 Nov;47(11):1540-6. doi: 10.1177/1060028013501144. Epub 2013 Nov 21. Review.

PMID:
24265264
4.

Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.

Yang H, Laurenza A, Williams B, Patten A, Hussein Z, Ferry J.

Epilepsy Res. 2015 Aug;114:122-30. doi: 10.1016/j.eplepsyres.2015.04.010. Epub 2015 May 1.

5.

Ponatinib in refractory Philadelphia chromosome-positive leukemias.

Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M.

N Engl J Med. 2012 Nov 29;367(22):2075-88. doi: 10.1056/NEJMoa1205127.

6.

Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.

Shakeri-Nejad K, Aslanis V, Veldandi UK, Mooney L, Pezous N, Brendani B, Juan A, Allison M, Perry R, Legangneux E.

Clin Ther. 2015 Nov 1;37(11):2489-2505.e2. doi: 10.1016/j.clinthera.2015.09.006. Epub 2015 Oct 27.

PMID:
26519230
7.

Ponatinib-induced neutrophilic panniculitis.

Zhang M, Hassan KM, Musiek A, Rosman IS.

J Cutan Pathol. 2014 Jul;41(7):597-601. doi: 10.1111/cup.12326. Epub 2014 Apr 8.

PMID:
24602068
8.

Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor.

Sanford D, Kantarjian H, Skinner J, Jabbour E, Cortes J.

Haematologica. 2015 Dec;100(12):e494-5. doi: 10.3324/haematol.2015.132845. Epub 2015 Sep 4. No abstract available.

9.

Losmapimod concentration-QT relationship in healthy volunteers: meta-analysis of data from six clinical trials.

Yang S, Beerahee M.

Eur J Clin Pharmacol. 2013 Jun;69(6):1261-7. doi: 10.1007/s00228-012-1469-1. Epub 2013 Jan 17.

PMID:
23325437
10.

Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.

Hofmann C, Banken L, Hahn M, Swearingen D, Nagel S, Martin-Facklam M.

Clin Ther. 2012 Oct;34(10):2061-71. doi: 10.1016/j.clinthera.2012.08.010. Epub 2012 Sep 12.

PMID:
22980315
11.

Identifying drug-induced repolarization abnormalities from distinct ECG patterns in congenital long QT syndrome: a study of sotalol effects on T-wave morphology.

Graff C, Andersen MP, Xue JQ, Hardahl TB, Kanters JK, Toft E, Christiansen M, Jensen HK, Struijk JJ.

Drug Saf. 2009;32(7):599-611. doi: 10.2165/00002018-200932070-00006.

PMID:
19530746
12.

Evaluation of the potential for QTc prolongation in patients with solid tumors receiving nivolumab.

Agrawal S, Waxman I, Lambert A, Roy A, Darbenzio R.

Cancer Chemother Pharmacol. 2016 Mar;77(3):635-41. doi: 10.1007/s00280-016-2980-3. Epub 2016 Feb 10.

PMID:
26861469
13.

Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.

Matz J, Graff C, Vainio PJ, Kallio A, Højer AM, Struijk JJ, Kanters JK, Andersen MP, Toft E.

Clin Drug Investig. 2011 Nov 1;31(11):799-811. doi: 10.2165/11592950-000000000-00000.

PMID:
21967071
14.

Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies.

Han TH, Chen R, Advani R, Berryman RB, Smith SE, Forero-Torres A, Rosenblatt JD, Smith MR, Zain J, Hunder NN, Engert A.

Cancer Chemother Pharmacol. 2013 Jul;72(1):241-9. doi: 10.1007/s00280-013-2192-z. Epub 2013 May 30.

15.

Thorough QT study of the effect of oral moxifloxacin on QTc interval in the fed and fasted state in healthy Japanese and Caucasian subjects.

Taubel J, Ferber G, Lorch U, Batchvarov V, Savelieva I, Camm AJ.

Br J Clin Pharmacol. 2014 Jan;77(1):170-9. doi: 10.1111/bcp.12168.

16.

Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers.

Peeters M, Janssen K, Kakuda TN, Schöller-Gyüre M, Lachaert R, Hoetelmans RM, Woodfall B, De Smedt G.

Ann Pharmacother. 2008 Jun;42(6):757-65. doi: 10.1345/aph.1K681. Epub 2008 Apr 29.

PMID:
18445705
17.

Safe and effective use of ponatinib in a patient with chronic myeloid leukemia and acute venous thromboembolism on therapeutic anti-coagulation.

Shomali W, Redmond C, Bogati S, Zimmerman C, Visconte V, Tabarroki A, Kalaycio M, Tiu RV.

Leuk Lymphoma. 2016;57(1):193-5. doi: 10.3109/10428194.2015.1036259. Epub 2015 Jun 18. No abstract available.

PMID:
25942382
18.

Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.

He YL, Zhang Y, Serra D, Wang Y, Ligueros-Saylan M, Dole WP.

Curr Med Res Opin. 2011 Jul;27(7):1453-63. doi: 10.1185/03007995.2011.585395. Epub 2011 May 24.

PMID:
21609207
19.

Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs.

Naing A, Veasey-Rodrigues H, Hong DS, Fu S, Falchook GS, Wheler JJ, Tsimberidou AM, Wen S, Fessahaye SN, Golden EC, Aaron J, Ewer MS, Kurzrock R.

Ann Oncol. 2012 Nov;23(11):2960-3. doi: 10.1093/annonc/mds130. Epub 2012 Jun 27.

20.

Effects of bilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study.

Graff C, Struijk JJ, Kanters JK, Andersen MP, Toft E, Tyl B.

Clin Drug Investig. 2012 May 1;32(5):339-51. doi: 10.2165/11599270-000000000-00000.

PMID:
22393898

Supplemental Content

Support Center